Authors

Latest:

Dr. Chien on Tucatinib in HER2+ Breast Cancer

A. Jo Chien, MD, associate clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of tucatinib (ONT-380) in the treatment of patients with HER2-positive breast cancer.

A. Karim Kader, MD, PhD

Latest:

Dr. Kader on PGS Stratifying Baseline Risk of Prostate Cancer in PLCO Trial

A. Karim Kader, MD, PhD, Minimally Invasive Surgery, Urology, Department of Surgery, University of California San Diego School of Medicine, discusses how prostate genetic score (PGS) stratifies baseline risk of prostate cancer and improves prostate-specific antigen (PSA) performance in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening trial.

A. Kei

A. Keith Stewart, MB ChB

Latest:

Clinical Trials in R/R Multiple Myeloma

Dr Joseph Mikhael and expert panel discuss key efficacy and safety outcomes of pivotal clinical trials evaluating treatment regimens in patients with R/R multiple myeloma.

A. Keith Stewart, MB, ChB, Mayo Clinic

A. Keith Stewart, MB, ChB, The Mayo Clinic in Phoenix Arizona

A. Oliver Sartor, MD

Latest:

Dr Sartor on Efficacy and Safety of Lutetium Lu 177 Vipivotide Tetraxetan in Taxane-Naive mCRPC

Oliver Sartor, MD, discusses updated efficacy findings from the phase 3 PSMAfore trial of lutetium Lu 177 vipivotide tetraxetan in patients with previously treated, taxane-naive metastatic castration-resistant prostate cancer.

A. Ruth He, MD, PhD, Georgetown University Medical Center

Aakanksha Prasad Asija, MD, MPH

Latest:

When Patients Refuse Treatment for Their Cancer

Quoting statistics seemed to be a refuge to me. The objectivity of the numbers provided a hiding place and a shelter, and they helped me maintain the emotional distance that my profession demanded.

Aarati Rao, MD

Latest:

A Day In the Life of a Pediatric Oncologist

As a practicing pediatric oncologist at an academic institute, every morning begins with optimism and a quest to win the day.

Aaron C. Logan, MD, PhD, University of California San Francisco

Aaron C. Logan, MD, PhD, University of California San Francisco Medical Sciences Building

Aaron E. Katz, MD, FACS

Latest:

Dr. Katz on Redefining Risk Stratification in Prostate Cancer

Aaron E. Katz, MD, FACS, discusses redefining risk stratification for men with prostate cancer.

Aaron Gerds, MD

Latest:

Dr Gerds on Efficacy Data Supporting the Use of Momelotinib in Myelofibrosis With Anemia

Aaron Gerds, MD, discusses data from the SIMPLIFY-1 and MOMENTUM trials which support the use of momelotinib in myelofibrosis with anemia.

Aaron Goodman, MD

Latest:

Dr. Goodman on the Need for Molecular Subtyping in T-Cell Lymphomas

Aaron Goodman, MD, discusses the need for molecular subtyping in T-cell lymphomas.

Aaron Logan, MD, PhD

Latest:

Clinical Trials and Real-World Data on Brexu-Cel

Panelists discuss how the dosing and lymphodepletion regimens of brexucabtagene autoleucel (brexu-cel), tisagenlecleucel (tisa-cel), and obecabtagene autoleucel (obe-cel) differ, with insights into obe-cel’s double infusion approach, as well as a deeper dive into the ZUMA-3 trial’s design and data updates with brexu-cel in relapsed/refractory acute lymphoblastic leukemia (R/R ALL).

Aaron S. Mansfield, MD

Latest:

Dr. Mansfield Discusses Ongoing Trials With Chemoimmunotherapy in Mesothelioma

Aaron S. Mansfield, MD, discusses ongoing trials with chemoimmunotherapy in mesothelioma.

Aaron S. Mansfield MD, Tobias Peikert, MD

Latest:

Potential Applications of Immune Checkpoint Blockade for Mesothelioma

Malignant pleural mesothelioma (MPM) is an inexorably progressive and almost universally fatal malignancy.

Aarti S. Bhardwaj, MD

Latest:

Common Adverse Effects of Anti-HER2 Therapies and Practical Management Recommendations

The benefits of trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-DM1) have all been well studied, but each drug also has its own set of complications and toxicities.

Aashini Master, DO

Latest:

Dr. Master on the Mediterranean Diet in Relation to Breast Cancer Risk

Aashini Master, DO, assistant clinical professor, Division of Hematology/Oncology, University of California, Los Angeles Medical Center, discusses the Mediterranean diet in relation to breast cancer risk.